

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
GENERAL ELECTRIC CAPITAL CORPORATION	10/28/2010
RECEIVING PARTY DATA	
Name:	EKR THERAPEUTICS, INC.
Street Address:	7 EAST FREDERICK PLACE
City:	CEDAR KNOLLS
State/Country:	NEW JERSEY
Postal Code:	07927
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	5500411
Patent Number:	5510330
CORRESPONDENCE DATA	
Fax Number:	(617)342-4001
Email:	jrobins@foley.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Michel Morency
Address Line 1:	111 Huntington Ave
Address Line 2:	Foley & Lardner LLP
Address Line 4:	Boston, MASSACHUSETTS 02199
ATTORNEY DOCKET NUMBER:	101296-0105
NAME OF SUBMITTER:	Jennifer L. Robins for Michel Morency
Total Attachments: 10 source=101296-0105release#page1.tif source=101296-0105release#page2.tif	

OP \$80.00 5500411

source=101296-0105release#page3.tif
source=101296-0105release#page4.tif
source=101296-0105release#page5.tif
source=101296-0105release#page6.tif
source=101296-0105release#page7.tif
source=101296-0105release#page8.tif
source=101296-0105release#page9.tif
source=101296-0105release#page10.tif

RELEASE OF SECURITY INTEREST IN PATENT

THIS RELEASE OF SECURITY INTEREST IN PATENT (this "Release") is made as of October 28, 2010 ("Effective Date") by **GENERAL ELECTRIC CAPITAL CORPORATION**, in its capacity as Collateral Agent for the Secured Parties ("Grantee"), in favor of **EKR THERAPEUTICS, INC.** ("Grantor"). All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Credit Agreement (as defined below).

WHEREAS, Grantor is party to that certain Credit Agreement, dated as of March 7, 2008, by and among Grantor, EKR Holdings, Inc., Grantee, for itself, as Lender, Collateral Agent and as Administrative Agent for the Lenders and L/C Issuers, and the other Lenders signatory thereto from time to time (as from time to time amended, restated, supplemented or otherwise modified, the "Credit Agreement");

WHEREAS, pursuant to the terms and conditions of that certain Guaranty and Security Agreement, dated as of March 7, 2008 (as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement"), Grantee holds a Lien against the intellectual property rights owned by Grantor;

WHEREAS, Grantor is also party to that certain Patent Security Agreement, dated as of March 7, 2008, by and among Grantor and Grantee, acting in its capacity as the Collateral Agent for the Secured Parties (as from time to time amended, restated, supplemented or otherwise modified, the "Patent Security Agreement"), which was recorded in the United States Patent and Trademark Office on December 15, 2008, at Reel/Frame 021976/0780, and pursuant to which Grantor mortgaged, pledged and hypothecated to Grantee, for itself and the benefit of the Secured Parties, a security interest in and Lien upon all of Grantee's right, title and interest in, to and under the Patent Collateral (as defined in the Patent Security Agreement), including, but not limited to, the Patents and Patent Applications identified on Exhibit A attached hereto (the "Patent Collateral"); and

WHEREAS, pursuant to the terms and conditions of that certain payoff letter, dated as of the date hereof, by and among Administrative Agent, Lenders, Grantee and the other Loan Parties signatory thereto, Grantee has consented to the release of its security interest in and Lien upon the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

1. Grantee, on its behalf and on behalf of the Secured Parties, hereby terminates and releases all of its or the Secured Parties' security interest in and Lien upon the Patent Collateral granted pursuant to the Patent Security Agreement.
2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantor, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Patent Collateral. Such assignment,

transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.

3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantor.

[Remainder of this page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

**GENERAL ELECTRIC CAPITAL
CORPORATION,**
as Grantee

By: 
Name: Kevin S. Blitz
Title: Duly Authorized Signatory

EXHIBIT A

1. Registered Patents

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Patent number</u>	<u>Patent registration date</u>
CARDENE				
Narcardipine Pharmaceutical Composition for Parenteral Administration	EKR Therapeutics, Inc. ("EKR")	United Kingdom	2228412	4/14/1993
Narcardipine Pharmaceutical Composition for Parenteral Administration	EKR	Belgium	9000217	5/12/1992
Narcardipine Pharmaceutical Composition for Parenteral Administration	EKR	Canada	2011063	7/6/1999
Narcardipine Pharmaceutical Composition for Parenteral Administration	EKR	United States of America	5,164,405	11/17/1992
Long Acting Calcium Channel Blocker Composition	EKR	United States of America	5,209,933	5/11/1993 Expired: 5/11/1997
Long Acting Formulation	EKR	Australia	604672	1/3/1991 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Austria	0231026	11/4/1992 Expired: 1/29/2007
Long Acting Formulation	EKR	Bahamas	872	8/17/1987 Abandoned: 1/29/2003
Sustained-Release Dihydropyridine Formulation	EKR	Belgium	0231026	11/4/1992 Expired: 1/29/2007
Long Lasting Dihydropyridine Calcium Channel Blockers	EKR	Canada	1285227	7/25/1991
Long Acting Formulation	EKR	Denmark	PR175216	7/12/2004 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	European Patent Convention	0231026	11/4/1992 Expired: 1/29/2007
Long Acting Formulation	EKR	Finland	88872	7/26/1993 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	France	0231026	11/4/1992 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Germany	P3782439.2	11/4/1992 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Greece	3006148	11/4/1992 Expired: 1/29/2007
Long Acting Formulation	EKR	Hungary	176709	9/1/1989 Expired: 1/29/2007
Long Acting Formulation	EKR	Ireland	61879	11/24/1997 Expired: 11/29/2007
Long Acting Formulation	EKR	Israel	81419	10/20/1991 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Italy	0231026	11/4/1992 Expired: 1/29/2007
Long Acting Formulation	EKR	Italy	1206876	5/11/1989 Expired: 1/29/2007
Long Acting Formulation	EKR	Japan	2524990	5/31/1996 Expired: 1/29/2007
Long Acting Formulation	EKR	Republic of Korea	37183	11/1/1990 Expired: 1/28/2007
Sustained-Release Dihydropyridine Formulation	EKR	Luxembourg	0231026	11/4/1992 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Netherlands	0231026	11/4/1992 Expired: 1/29/2007

Exhibit A to Release of Security Interest in Patent

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Patent number</u>	<u>Patent registration date</u>
Long Acting Formulation	EKR	New Zealand	219090	9/12/1990 Expired: 1/29/2007
Long Acting Formulation	EKR	Norway	174325	4/27/1994 Expired: 1/29/2007
Long Acting Formulation	EKR	Philippines	26366	6/1/1992
Long Acting Formulation	EKR	Philippines	27242	5/4/1993
Long Acting Formulation	EKR	Portugal	84213	9/14/1988 Expired: 1/29/2007
Long Acting Formulation	EKR	South Africa	87/0668	9/28/1988 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Spain	0231026	11/4/1992 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Sweden	0231026	11/4/1992 Expired: 1/29/2007
Sustained-Release Dihydropyridine Formulation	EKR	Switzerland	0231026	11/4/1992 Expired: 1/29/1007
Long Acting Formulation	EKR	Taiwan	030154	1/16/1989 Expired: 1/27/2007
Sustained-Release Dihydropyridine Formulation	EKR	United Kingdom	0231026	11/4/1992 Expired: 1/29/2007
Method of Preparing Long Acting Formulation	EKR	United States of America	4,940,556	7/10/1990
Long Acting Nicardipine Hydrochloride Formulation	EKR	United States of America	5,198,226	3/30/1993
RETAVASE				
Derivative of Tissue-Type Plasminogen Activator	EKR	Canada	2025900	1/19/1999
Thrombolytically Active Non-Glycosylated Protein	EKR	United States of America	5,223,256	6/29/1993
Pharmaceutical Packaging United Containing Plasminogen Activators for Multiple Bolus Administration	EKR	Canada	2,107,476	12/18/2007
Method of Treating Thromboembolic Conditions by Inhibiting Reocclusion Via the Use of Multiple Bolus Administration of Thrombolytically Active Proteins	EKR	United States of America	5,500,411	3/19/1996
Combinations of Thrombolytically Active Proteins and Non-Heparin Anticoagulants, and Uses Thereof	EKR	United States of America	5,510,330	4/23/1996
Modified Human T-PA	EKR	Canada	1341458	10/12/2004
Tissue Plasminogen Activator	EKR	United States of America	5,648,250	7/15/1997
Tissue Plasminogen Activator	EKR	United States of America	5,840,533	11/24/1998
ULARITIDE				
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	EKR	Belgium	0763061	10/30/2002
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	EKR	European Patent Convention	0763061	10/30/2002
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	Pharis Biotec GmbH	France	0763061	10/30/2002
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	Pharis Biotec GmbH	Germany	0763061	10/30/2002
Process and Intermediate Products for Preparing Cardiodilatin	Pharis Biotec GmbH	Italy	0763061	10/30/2002

Exhibit A to Release of Security Interest in Patent

PATENT
REEL: 028178 FRAME: 0281

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Patent number</u>	<u>Patent registration date</u>
Fragments, and Highly Purified Cardiodilatin Fragments				
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	Pharis Biotec GmbH	Netherlands	0763061	10/30/2002
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	Pharis Biotec GmbH	Spain	0763061	10/30/2002
A Process and Intermediate Products for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of the Same	Pharis Biotec GmbH	Taiwan	107084	1/19/2000
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	Pharis Biotec GmbH	United Kingdom	0763061	10/30/2002
A Process and Intermediate Products for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of the Same	Pharis Biotec GmbH	United States of America	5,767,239	6/16/1998
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	European Patent Convention	0349545	2/3/1993
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	France	0349545	2/3/1993
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	Germany	0349545	2/3/1993
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	Italy	0349545	2/3/1993
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	Japan	2819467	8/28/1998
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	United Kingdom	0349545	2/3/1993
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	United States of America	5,449,751	9/12/1995
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	United States of America	5,665,861	9/9/1997
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	European Patent Convention	1207901	10/8/2003
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	France	1207901	10/8/2003
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	Germany	1207901	10/8/2003
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	Italy	1207901	10/8/2003

Exhibit A to Release of Security Interest in Patent

PATENT
REEL: 028178 FRAME: 0282

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Patent number</u>	<u>Patent registration date</u>
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	United Kingdom	1207901	10/8/2003
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	United States of America	7,033,997	4/25/2006
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Belgium	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	European Patent Convention	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	France	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Germany	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Italy	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Japan	3172188	3/23/2001
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Netherlands	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Spain	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	United Kingdom	0642349	8/5/1998
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	United States of America	5,571,789	11/5/1996
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	European Patent Convention	1223968	5/7/2003
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	France	1223968	5/7/2003
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	Germany	1223968	5/7/2003
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	Italy	1223968	5/7/2003
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	Spain	1223968	5/7/2003
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	United Kingdom	1223968	5/7/2003
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	United States of America	6,831,064	12/24/2004
Composition Containing Cardiodilatin or Fragments Thereof and Methods of Obtaining Cardiodilatin	Pharis Biotec GmbH	United States of America	4,782,044	11/1/1988 Expired: 11/1/2005
Method for Determining Cardiodilatin and Fragments Thereof and Antibodies Useful in Determination of Cardiodilatin and its Fragments	Pharis Biotec GmbH	United States of America	4,895,932	1/23/1990
Cardiodilatin, a New Peptide Hormone and Process for its Preparation	Pharis Biotec GmbH	United States of America	4,751,284	6/14/1988
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	European Patent Convention	0386076	2/3/1993
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	France	0386076	2/3/1993
Phosphorylated Derivatives of	Pharis Biotec	Germany	0386076	2/3/1993

Exhibit A to Release of Security Interest in Patent

PATENT
REEL: 028178 FRAME: 0283

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Patent number</u>	<u>Patent registration date</u>
Cardiodilatin/ANF Peptides	GmbH			
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	Italy	0386076	2/3/1993
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	Japan	2727098	12/12/1998
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	United Kingdom	0386076	2/3/1993
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	United States of America	5,461,142	10/24/1995

2. Patent Applications

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Application number</u>	<u>Application date</u>
CARDENE				
Pre-Mixed, Ready-to-Use Pharmaceutical Compositions	Joint Ownership	Patent Cooperation Treaty	US 2007/009549	4/18/2007
Pre-Mixed, Ready-to-Use Injectable Cardiac Formulation	Joint Ownership	United States of America	60/730,593	10/26/2005 Abandoned: 9/8/2006
Pre-Mixed, Ready-to-Use Injectable Cardiac Formulation	Joint Ownership	United States of America	60/793,074	4/18/2006 Expired: 4/18/2007
Pre-Mixed, Ready-to-Use Pharmaceutical Compositions	Joint Ownership	United States of America	11/788,076	4/18/2007
Narcardipine Pharmaceutical Composition for Parenteral Administration	EKR	United States of America	07/317,171	2/28/1989 Abandoned: 10/22/1990
Long Acting Calcium Channel Blocker Composition	EKR	United States of America	07/464,103	1/10/1990 Abandoned: 9/13/1991
Long Acting Formulation	EKR	European Patent Convention	87118948.6	12/12/1987 Abandoned: 2/12/1992
Long Acting Formulation	EKR	United States of America	06/940,878	12/10/1986 Abandoned: 2/2/1988
Long Acting Formulation	EKR	United States of America	07/008,900	1/30/1987 Abandoned
Long Acting Formulation	EKR	United States of America	07/526,862	5/22/1990 Abandoned: 11/12/1991
Long Acting Formulation	EKR	United States of America	06/823,896	1/30/1986 Abandoned: 2/2/1988
Pre-Mixed, Ready-to-Use IV Bolus Compositions and Methods of Use	EKR	Patent Cooperation Treaty	US2007/066897	4/18/2007 Pending
Pre-Mixed, Ready-to-Use IV Bolus Compositions and Methods of Use	EKR	United States of America	11/737,067	4/18/2007 Pending
ULARITIDE				
Use of Natriuretic Peptide for Treating Heart Failure	EKR	European Patent Convention	06749753.7	4/7/2007
Use of Natriuretic Peptide for Treating Heart Failure	EKR	Patent Cooperation Treaty	US2006/013471	4/7/2006
Use of Natriuretic Peptide for Treating Heart Failure	EKR	United States of America	60/669,786	4/7/2005 Expired: 4/7/2006
Use of Natriuretic Peptide for Treating Heart Failure	EKR	United States of America	60/669,751	4/8/2005 Expired: 4/8/2006
Use of Natriuretic Peptide for Treating Heart Failure	EKR	United States of America	60/732,585	11/1/2005 Expired: 11/1/2006
Use of Natriuretic Peptide for Treating Heart Failure	EKR	United States of America	11/400,696	4/7/2006:
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	EKR	Canada	2191612	5/30/1995 Pending
Process and Intermediate Products	Pharis Biotec	Japan	8-500318	5/30/1995

Exhibit A to Release of Security Interest in Patent

PATENT
REEL: 028178 FRAME: 0284

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Application number</u>	<u>Application date</u>
for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	GmbH			Abandoned
Process for Production of Cardiodilatin Fragment	Pharis Biotec GmbH	Japan	2005-202136	5/30/1995
Process and Intermediate Products for Preparing Cardiodilatin Fragments, and Highly Purified Cardiodilatin Fragments	Pharis Biotec GmbH	Patent Cooperation Treaty	EP1995/002050	5/30/1995
A Process and Intermediate Products for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of the Same	Pharis Biotec GmbH	United States of America	09/027,777	2/23/1998 Abandoned
A Process and Intermediate Products for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of the Same	Pharis Biotec GmbH	United States of America	11/084,190	3/21/2005
A Process and Intermediate Products for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of the Same	Pharis Biotec GmbH	United States of America	11/881,669	7/27/2007 Pending
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	Patent Cooperation Treaty	EP1988/000144	2/27/1988
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	United States of America	07/795,248	11/18/1991 Abandoned
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	United States of America	07/994,084	12/16/1992 Abandoned
Cardiodilatin Fragment, Process for Preparing Same and Use Thereof	Pharis Biotec GmbH	United States of America	07/401,401	9/1/1989 Abandoned
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	Patent Cooperation Treaty	EP2000/008545	9/1/2000
Use of Natriuretic Peptides as Antibiotically Effective Substances for Treating Bacterial Infections	Pharis Biotec GmbH	United States of America	10/069,128	3/4/2002 Abandoned: 3/3/2005
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Canada	2135614	5/12/1993
Use of Urodilatin in Pulmonary and Bronchial Diseases	Pharis Biotec GmbH	Patent Cooperation Treaty	EP1993/001189	5/12/1993
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	Japan	2001-532793	10/24/2000 Pending
Use of Urodilatin for Treating Chronic Kidney Failure with Residual Kidney Functions	Pharis Biotec GmbH	Patent Cooperation Treaty	EP2000/010462	10/24/2000
Phosphorylated Derivatives of Cardiodilatin/ANF Peptides	Pharis Biotec GmbH	Patent Cooperation Treaty	EP1988/001000	11/4/1988
Conjugate of Natriuretic Peptide and Antibody Constant Region	EKR	European Patent Convention	US07/88404	12/20/2007 Pending
Conjugate of Natriuretic Peptide and Antibody Constant Region	EKR	United States of America	11,960,424	12/19/2007 Pending
Conjugate of Natriuretic Peptide and Antibody Constant Region	EKR	European Patent Convention	60/876,913	12/21/2006 Pending
Room Temperature Stable,	EKR	United States of America	61/014,986	12/19/2007

Exhibit A to Release of Security Interest in Patent

PATENT
REEL: 028178 FRAME: 0285

<u>Title</u>	<u>Assignee Name</u>	<u>Jurisdiction</u>	<u>Application number</u>	<u>Application date</u>
Lyophilized Natriuretic Peptide Formulations				Pending

Exhibit A to Release of Security Interest in Patent

RECORDED: 05/09/2012

PATENT
REEL: 028178 FRAME: 0286